BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Endo Pharmaceuticals (ENDP) Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems, Inc. (AMMD)


8/9/2011 11:53:04 AM

CHADDS FORD, Pa., Aug. 9, 2011 /PRNewswire/ --

  • Total quarterly revenues of $608 million increase 53 percent versus prior year;
  • Reported quarterly diluted EPS of $0.44 versus $0.44 for prior year;
  • Adjusted diluted EPS of $1.05 reflecting growth of 30 percent from 2010;
  • Company increases 2011 revenue guidance to a range of $2.72 to $2.80 billion; and
  • Company increases 2011 adjusted diluted EPS guidance to a range of $4.55 to $4.65 and Reported or GAAP diluted EPS to a range $2.22 to $2.32 reflecting continued strong growth in core operations and the recent acquisition of American Medical Systems.

Endo Pharmaceuticals (Nasdaq: ENDP) today reported financial results for the second quarter of 2011.

Total revenues during the second quarter of 2011 increased 53 percent to $607.6 million, compared with $396.5 million in the same quarter of 2010. Net income for the three months ended June 30, 2011 was $54.6 million, compared with $51.5 million in the comparable 2010 period. As detailed in the supplemental financial information below, adjusted net income for the three months ended June 30, 2011, was $128.7 million, compared with $94.7 million in the same period in 2010. Reported diluted earnings per share for the quarter ended June 30, 2011 were $0.44 compared with $0.44 in the second quarter of 2010. Adjusted diluted earnings per share for the same period were $1.05 compared with $0.81 reported in 2010.


($ in thousands, except per share amounts)








2nd Quarter


Six Months Ended June 30



2011

2010

Change

2011

2010

Change

Total Revenues

$607,611

$396,524

53%

$1,167,637

$760,936

53%

Reported Net Income

54,583

51,460

6%

110,370

111,815

-1%

Reported Diluted EPS

0.44

0.44

0%

0.91

0.95

-4%

Adjusted Net Income

128,700

94,699

36%

248,878

181,881

37%

Adjusted Diluted EPS

1.05

$0.81

30%

2.04

$1.55

32%




"Endo had a strong second quarter, with record revenues and earnings in our legacy branded pharmaceuticals pain franchise, which had double-digit revenue growth year-over-year," said Dave Holveck, president and CEO of Endo. "I remain very positive about the growth prospects of our new integrated business in branded pharmaceuticals, generics, and devices and services. I believe our strategy has positioned us well in the new healthcare environment to provide the right path to sustainable, long-term growth and to becoming one of our industry's premier providers of comprehensive healthcare solutions."

BRANDED PHARMACEUTICALS

Branded pharmaceutical sales of $398.3 million for the second quarter represented an increase of 8% versus the prior year. These results reflect strong commercial performance in our branded pain franchise where net sales grew 13% year-over-year, with a strong second quarter performance by OPANA® ER, and Voltaren® Gel. OPANA ER net sales grew 64% on prescription growth of 57%. Voltaren Gel net sales grew 39%. These are robust results for established brands that continue to produce cash flows that enable us to invest in our future growth.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES